COVID-19 Partnerships Without Formal Contracts Pose Risks, From Potential Liability To IP Issues
Companies are racing to co-develop coronavirus treatments before finalizing deal teams. These team-ups raise questions about what happens after the pandemic subsides.
You may also be interested in...
In the short term, public-private partnerships engaged in the coronavirus response will be judged on whether there are effective treatments for COVID-19. But the long-term impact may be as a test of whether collaborative models can work when the stakes are high.
Scientists and lawyers ask companies to temporarily license their IP for free, as others advocate compulsory licenses; real issue may be the ability to make a COVID-19 treatment or vaccine widely available.
Scrip talked to George Scangos about his dual roles in the pandemic response, helming Vir as the company tests antibody and siRNA approaches while working with BIO to facilitate coronavirus collaborations.